Human Cancer Immunotherapy with PD-1/PD-L1 Blockade

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Programmed cell death-1 (PD-1) ligation to PD-L1/PD-L2 inhibits T-cell activation, essential for immune tolerance.
• Elevated PD-1 and PD-L1 expression in tumors creates a suppressive microenvironment, promoting cancer growth.
• The PD-1 axis is a key target for modulating immune responses against cancer.

Purpose of the Study:

• To review the clinical progress of PD-1 axis blockade strategies.
• To evaluate the effectiveness of PD-1 axis inhibitors in various cancer types.
• To summarize current advancements in antitumor immunotherapy targeting the PD-1 pathway.

Main Methods:

• Review of clinical trial data on PD-1 axis blockade.
• Analysis of therapeutic strategies including PD-L2 fusion proteins and monoclonal antibodies against PD-1 or PD-L1.
• Evaluation of treatment outcomes across different tumor types.

Main Results:

• PD-1 axis blockade has been clinically evaluated in numerous tumor types.
• Monoclonal antibodies targeting PD-1 or PD-L1, and PD-L2 fusion proteins are key therapeutic agents.
• The effectiveness of these blockade strategies in antitumor immunotherapy is under ongoing investigation.

Conclusions:

• The PD-1 axis represents a significant target for cancer immunotherapy.
• Clinical trials are actively exploring the efficacy of PD-1 axis blockade in diverse malignancies.
• Further research is warranted to optimize PD-1 pathway inhibition for enhanced antitumor responses.